After losing significant ground to rival Eli Lilly in the GLP-1 space over the past two years, Novo Nordisk is defending the one arena it now dominates — oral therapeutics. But with Lilly preparing to ...

For many Americans struggling to lose weight, powerful new medications are changing the game. With roughly 40% of U.S. adults living with obesity, according to the Centers for Disease Control ...

Both Lilly and Viking are great buys today and could have bright futures in the weight loss drug market. Though Viking hasn't ...

Eli Lilly’s new oral pill, orforglipron, led to up to 8% weight loss in clinical trials, outperforming existing oral semaglutide alternatives. View on euronews ...

Reports say Novo Nordisk and Hims could announce a new partnership as soon as Monday to sell weight-loss drugs on the Hims platform.

Novo Nordisk stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its primary target.

Americans want to lose weight but continuously fall short. As I've chronicled in this column year after year, weight-loss and related goals like exercising more and eating better are among the top New ...

The FDA’s approval of Wegovy on June 4, 2021, ended a seven-year drought in new obesity treatments and set off a chain reaction that has reshaped how doctors, patients, and insurers think about excess ...

"I want the weight off and it's coming off!" the Grammy winner said Backgrid; DJ Khaled/Instagram DJ Khaled shared before-and-after photos of his recent weight loss The 50-year-old producer credits ...

Evelyn Parr received funding from the Australian government's Medical Research Future Fund and the Diabetes Australia Research Program for work on time-restricted eating. Intermittent fasting has ...